WEBKISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor...
- [PDF]
kisqali - Novartis
WEBKISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or
WEBThe KISQALI® FEMARA® CO-PACK is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic
WEBKISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic...
WEBWhat is KISQALI? KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with: • an aromatase inhibitor as the first endocrine-based therapy; or.
KISQALI (Novartis Pharmaceuticals Corporation): FDA Package Insert
WEBAug 24, 2023 · The recommended dose of KISQALI is 600 mg (three 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. KISQALI can be taken with or without food [see Clinical Pharmacology (12.3)].
WEBKISQALI is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative advanced or metastatic breast cancer in...
eBC and mBC Treatment | KISQALI (ribociclib)
WEBKISQALI® (ribociclib) for HR+, HER2- Metastatic Breast Cancer. This site is for US residents only. Patient Support Line 1-800-282-7630, Monday – Friday: 9 AM – 5 PM ET. KISQALI is proven to help premenopausal and postmenopausal women, and men, with HR+, HER2- metastatic breast cancer.
Kisqali: Package Insert - Drugs.com
WEBAug 5, 2024 · Kisqali package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
WEBKisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
Skip to content